

# Circulating Fetal Cell-Free DNA Fractions Differ in Auto X

Clinical Chemistry

60, 243-250

DOI: [10.1373/clinchem.2013.207951](https://doi.org/10.1373/clinchem.2013.207951)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Non-Invasive Prenatal Testing Using Cell Free DNA in Maternal Plasma: Recent Developments and Future Prospects. <i>Journal of Clinical Medicine</i> , 2014, 3, 537-565.	1.0	101
2	Noninvasive prenatal testing: need for informed enthusiasm. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 211, 577-580.	0.7	9
3	Noninvasive Prenatal Testing Using Cell-free DNA in Maternal Circulation. <i>Journal of Fetal Medicine</i> , 2014, 1, 107-111.	0.1	3
4	Maternal fetal cellular trafficking. <i>Current Opinion in Pediatrics</i> , 2014, 26, 377-382.	1.0	59
5	Circulating fetal cell-free DNA and prenatal molecular diagnostics: are we ready for consensus?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 609-11.	1.4	3
6	Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis. <i>BMJ Open</i> , 2014, 4, e005922.	0.8	63
7	Review: Cell-free fetal DNA in the maternal circulation as an indication of placental health and disease. <i>Placenta</i> , 2014, 35, S64-S68.	0.7	179
8	DNA Sequencing versus Standard Prenatal Aneuploidy Screening. <i>New England Journal of Medicine</i> , 2014, 370, 799-808.	13.9	554
9	Theoretical performance of non-invasive prenatal testing for chromosome imbalances using counting of cell-free DNA fragments in maternal plasma. <i>Prenatal Diagnosis</i> , 2014, 34, 778-783.	1.1	67
10	Integration of Noninvasive DNA Testing for Aneuploidy into Prenatal Care: What Has Happened Since the Rubber Met the Road?. <i>Clinical Chemistry</i> , 2014, 60, 78-87.	1.5	139
11	Stability of cell-free DNA from maternal plasma isolated following a single centrifugation step. <i>Prenatal Diagnosis</i> , 2014, 34, 1283-1288.	1.1	25
12	RAPIDR: an analysis package for non-invasive prenatal testing of aneuploidy. <i>Bioinformatics</i> , 2014, 30, 2965-2967.	1.8	28
13	Noninvasive Prenatal Screening by Next-Generation Sequencing. <i>Annual Review of Genomics and Human Genetics</i> , 2014, 15, 327-347.	2.5	31
14	Use of Copy Number Deletion Polymorphisms to Assess DNA Chimerism. <i>Clinical Chemistry</i> , 2014, 60, 1105-1114.	1.5	20
15	RECENT DEVELOPMENTS IN NON-INVASIVE PRENATAL DIAGNOSIS AND TESTING. <i>Fetal and Maternal Medicine Review</i> , 2014, 25, 295-317.	0.3	4
17	Statistical Approach to Decreasing the Error Rate of Noninvasive Prenatal Aneuploid Detection caused by Maternal Copy Number Variation. <i>Scientific Reports</i> , 2015, 5, 16106.	1.6	15
18	Factors affecting levels of circulating cell-free fetal DNA in maternal plasma and their implications for noninvasive prenatal testing. <i>Prenatal Diagnosis</i> , 2015, 35, 816-822.	1.1	110
19	Maternal mosaicism for a large segmental duplication of 18q as a secondary finding following noninvasive prenatal testing and implications for test accuracy. <i>Prenatal Diagnosis</i> , 2015, 35, 986-989.	1.1	15

#	ARTICLE	IF	CITATIONS
20	Position statement from the Chromosome Abnormality Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. <i>Prenatal Diagnosis</i> , 2015, 35, 725-734.	1.1	243
21	An Economic Analysis of Cell-Free DNA Non-Invasive Prenatal Testing in the US General Pregnancy Population. <i>PLoS ONE</i> , 2015, 10, e0132313.	1.1	44
22	Utilization of Benchtop Next Generation Sequencing Platforms Ion Torrent PGM and MiSeq in Noninvasive Prenatal Testing for Chromosome 21 Trisomy and Testing of Impact of In Silico and Physical Size Selection on Its Analytical Performance. <i>PLoS ONE</i> , 2015, 10, e0144811.	1.1	41
23	Unexplained False Negative Results in Noninvasive Prenatal Testing: Two Cases Involving Trisomies 13 and 18. <i>Case Reports in Genetics</i> , 2015, 2015, 1-7.	0.1	11
24	Cell-free fetal DNA: the new tool in fetal medicine. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 45, 499-507.	0.9	38
25	High-resolution characterization of sequence signatures due to non-random cleavage of cell-free DNA. <i>BMC Medical Genomics</i> , 2015, 8, 29.	0.7	107
26	The Amniotic Fluid Transcriptome as a Guide to Understanding Fetal Disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a023101-a023101.	2.9	32
27	Implementation of whole genome massively parallel sequencing for noninvasive prenatal testing in laboratories. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 111-124.	1.5	15
28	Noninvasive prenatal testing using a novel analysis pipeline to screen for all autosomal fetal aneuploidies improves pregnancy management. <i>European Journal of Human Genetics</i> , 2015, 23, 1286-1293.	1.4	108
29	Circulating cell free DNA testing: are some test failures informative?. <i>Prenatal Diagnosis</i> , 2015, 35, 289-293.	1.1	79
30	Noninvasive Prenatal Testing and Incidental Detection of Occult Maternal Malignancies. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 162.	3.8	334
31	Cell-free DNA screening for fetal aneuploidy as a clinical service. <i>Clinical Biochemistry</i> , 2015, 48, 932-941.	0.8	75
32	Effects of Maternal and Fetal Characteristics on Cell-Free Fetal DNA Fraction in Maternal Plasma. <i>Reproductive Sciences</i> , 2015, 22, 1429-1435.	1.1	85
33	Cell-free DNA Analysis for Noninvasive Examination of Trisomy. <i>New England Journal of Medicine</i> , 2015, 372, 1589-1597.	13.9	639
34	Copy-Number Variation and False Positive Prenatal Aneuploidy Screening Results. <i>New England Journal of Medicine</i> , 2015, 372, 1639-1645.	13.9	118
36	Single Nucleotide Polymorphism-Based Analysis of Cell-Free Fetal DNA in 3000 Cases from Germany and Austria. <i>Ultrasound International Open</i> , 2015, 01, E8-E11.	0.3	13
37	Positive predictive value of non-invasive prenatal screening for fetal chromosome disorders using cell-free DNA in maternal serum: independent clinical experience of a tertiary referral center. <i>BMC Medicine</i> , 2015, 13, 129.	2.3	35
38	Feasibility of noninvasive prenatal testing for common fetal aneuploidies in an early gestational window. <i>Clinica Chimica Acta</i> , 2015, 439, 24-28.	0.5	16

#	ARTICLE	IF	CITATIONS
39	Recent advances in prenatal genetic screening and testing. F1000Research, 2016, 5, 2591.	0.8	51
40	The importance of determining the limit of detection of noninvasive prenatal testing methods. Prenatal Diagnosis, 2016, 36, 304-311.	1.1	45
41	Validation of two-channel sequencing-by-synthesis for noninvasive prenatal testing of fetal whole and partial chromosome aberrations. Prenatal Diagnosis, 2016, 36, 216-223.	1.1	2
42	Feto-Maternal Cell Trafficking and Labor. Pancreatic Islet Biology, 2016, , 33-45.	0.1	1
43	Copy-Number Variation and False Positive Prenatal Screening Results. New England Journal of Medicine, 2016, 375, 97-98.	13.9	11
44	Cell-Free DNA Screening. Obstetrical and Gynecological Survey, 2016, 71, 477-487.	0.2	49
45	Maternal Plasma DNA and RNA Sequencing for Prenatal Testing. Advances in Clinical Chemistry, 2016, 74, 63-102.	1.8	25
46	Trends in Invasive Prenatal Diagnosis: Effect of Sequential Screening and Noninvasive Prenatal Testing. Fetal Diagnosis and Therapy, 2016, 39, 292-296.	0.6	13
47	Comment on "The importance of determining the limit of detection of noninvasive prenatal testing methods". Prenatal Diagnosis, 2016, 36, 896-897.	1.1	2
48	Response to "The importance of determining the limit of detection of noninvasive prenatal testing methods". Prenatal Diagnosis, 2016, 36, 898-899.	1.1	0
49	Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics. Genetics in Medicine, 2016, 18, 1056-1065.	1.1	541
52	Screening for trisomies by cell-free DNA testing of maternal blood: consequences of a failed result. Ultrasound in Obstetrics and Gynecology, 2016, 47, 698-704.	0.9	124
53	Limited Clinical Utility of Non-invasive Prenatal Testing for Subchromosomal Abnormalities. American Journal of Human Genetics, 2016, 98, 34-44.	2.6	101
54	Quantitation of fetal DNA fraction in maternal plasma using circulating single molecule amplification and re-sequencing technology (cSMART). Clinica Chimica Acta, 2016, 456, 151-156.	0.5	18
55	Fetal cell-free DNA fraction in maternal plasma is affected by fetal trisomy. Journal of Human Genetics, 2016, 61, 647-652.	1.1	59
56	Follow-up of multiple aneuploidies and single monosomies detected by noninvasive prenatal testing: implications for management and counseling. Prenatal Diagnosis, 2016, 36, 203-209.	1.1	50
57	First-Trimester Ultrasound. , 2016, , .		3
59	Aneuploidy screening by non-invasive prenatal testing in twin pregnancy. Ultrasound in Obstetrics and Gynecology, 2017, 49, 470-477.	0.9	45

#	ARTICLE	IF	CITATIONS
60	Non-invasive prenatal diagnosis of beta-thalassemia by semiconductor sequencing: a feasibility study in the sardinian population. <i>European Journal of Human Genetics</i> , 2017, 25, 600-607.	1.4	25
61	Recommended practice for laboratory reporting of non-invasive prenatal testing of trisomies 13, 18 and 21: a consensus opinion. <i>Prenatal Diagnosis</i> , 2017, 37, 699-704.	1.1	19
62	Noninvasive prenatal screening at low fetal fraction: comparing whole-genome sequencing and single-nucleotide polymorphism methods. <i>Prenatal Diagnosis</i> , 2017, 37, 482-490.	1.1	35
63	The Significance of Test Failures in Noninvasive Prenatal Screening for Fetal Aneuploidy Using Cell-free DNA. <i>Journal of Fetal Medicine</i> , 2017, 4, 13-18.	0.1	0
64	Performance of the neoBona test: a new paired-end massively parallel shotgun sequencing approach for cell-free DNA-based aneuploidy screening. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 49, 460-464.	0.9	23
65	Optimized short digestion protocol for free fetal DNA detection using methylation-dependent markers. <i>Laboratoriums Medizin</i> , 2017, 41, 195-203.	0.1	2
66	Rare autosomal trisomies, revealed by maternal plasma DNA sequencing, suggest increased risk of feto-placental disease. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	122
67	Enhanced First Trimester Screening for Trisomy 21 with Contingent Cell-Free Fetal DNA: A Comparative Performance and Cost Analysis. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2017, 39, 742-749.	0.3	11
68	Transcriptome landscape of human primary monocytes at different sequencing depth. <i>Genomics</i> , 2017, 109, 463-470.	1.3	9
69	Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women. <i>The Cochrane Library</i> , 2017, 11, CD011767.	1.5	67
70	Non-invasive prenatal diagnosis of thalassemias using maternal plasma cell free DNA. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2017, 39, 63-73.	1.4	42
71	Clinical utility of non-invasive prenatal testing in pregnancies with ultrasound anomalies. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 49, 721-728.	0.9	54
72	What are the most common first-trimester ultrasound findings in cases of Turner syndrome?. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2017, 30, 1632-1636.	0.7	10
73	Noninvasive Cell-Free DNA Prenatal Testing for Fetal Aneuploidy in Maternal Blood. , 2017, , 423-443.		0
74	Blood biomarkers in ischemic stroke: potential role and challenges in clinical practice and research. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2018, 55, 294-328.	2.7	85
75	Non-invasive Prenatal Testing: A Unique Approach with Single Nucleotide Polymorphism. <i>Journal of Fetal Medicine</i> , 2018, 05, 113-119.	0.1	0
76	Prenatal cell-free DNA screening test failures: a systematic review of failure rates, risks of Down syndrome, and impact of repeat testing. <i>Genetics in Medicine</i> , 2018, 20, 1312-1323.	1.1	40
77	Have we done our last amniocentesis? Updates on cell-free DNA for Down syndrome screening. <i>Pediatric Radiology</i> , 2018, 48, 461-470.	1.1	14

#	ARTICLE	IF	CITATIONS
78	Factors affecting cell-free DNA fetal fraction and the consequences for test accuracy. Journal of Maternal-Fetal and Neonatal Medicine, 2018, 31, 1865-1872.	0.7	63
79	Contingent first-trimester screening for aneuploidies with cell-free DNA in a Danish clinical setting. Ultrasound in Obstetrics and Gynecology, 2018, 51, 470-479.	0.9	42
80	Implications of failure to achieve a result from prenatal maternal serum cell-free DNA testing: a historical cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2018, 125, 848-855.	1.1	37
81	Screening for fetal chromosomal and subchromosomal disorders. Seminars in Fetal and Neonatal Medicine, 2018, 23, 85-93.	1.1	10
82	Informative priors on fetal fraction increase power of the noninvasive prenatal screen. Genetics in Medicine, 2018, 20, 817-824.	1.1	11
83	Sequencing of Circulating Cell-free DNA during Pregnancy. New England Journal of Medicine, 2018, 379, 464-473.	13.9	221
84	Factors Associated With Informative Redraw After an Initial No Result in Noninvasive Prenatal Testing. Obstetrics and Gynecology, 2018, 132, 428-435.	1.2	40
85	A Paradigm Shift: Considerations in Prenatal Cell-Free DNA Screening. journal of applied laboratory medicine, The, 2018, 2, 784-796.	0.6	1
86	Development of a comprehensive noninvasive prenatal test. Genetics and Molecular Biology, 2018, 41, 545-554.	0.6	8
87	Isochromosome 21q is overrepresented among false-negative cell-free DNA prenatal screening results involving Down syndrome. European Journal of Human Genetics, 2018, 26, 1490-1496.	1.4	16
88	Incognito: Are Microchimeric Fetal Stem Cells that Cross Placental Barrier Real Emissaries of Peace?. Stem Cell Reviews and Reports, 2018, 14, 632-641.	5.6	14
89	Fetal fraction-based risk algorithm for non-invasive prenatal testing: screening for trisomies 13 and 18 and triploidy in women with low cell-free fetal DNA. Ultrasound in Obstetrics and Gynecology, 2019, 53, 73-79.	0.9	36
90	Combination of Fetal Fraction Estimators Based on Fragment Lengths and Fragment Counts in Non-Invasive Prenatal Testing. International Journal of Molecular Sciences, 2019, 20, 3959.	1.8	13
91	The Effect of Freezing on Non-invasive Prenatal Testing. Scientific Reports, 2019, 9, 6962.	1.6	4
92	Factors affecting cell-free DNA fetal fraction: statistical analysis of 13,661 maternal plasmas for non-invasive prenatal screening. Human Genomics, 2019, 13, 62.	1.4	37
93	Performance of semiconductor sequencing platform for non-invasive prenatal genetic screening for fetal aneuploidy: results from a multicenter prospective cohort study in a clinical setting. Ultrasound in Obstetrics and Gynecology, 2019, 54, 246-254.	0.9	9
94	Combining count- and length-based z-scores leads to improved predictions in non-invasive prenatal testing. Bioinformatics, 2019, 35, 1284-1291.	1.8	12
95	Noninvasive Prenatal Testing by Cell-Free DNA: Technology, Biology, Clinical Utility, and Limitations. , 2019, , 627-652.		1

#	ARTICLE	IF	CITATIONS
96	Noninvasive Prenatal Testing for Genetic Diseases. , 2019, , 597-625.		1
97	Noninvasive Screening for Cytogenetic Disorders (Fetal Aneuploidy Including Microdeletions). , 2020, , 202-213.e3.		0
98	Noninvasive prenatal screening for patients with high body mass index: Evaluating the impact of a customized whole genome sequencing workflow on sensitivity and residual risk. Prenatal Diagnosis, 2020, 40, 333-341.	1.1	10
99	Clinical experience across the fetalâ€fraction spectrum of a nonâ€invasive prenatal screening approach with low testâ€failure rate. Ultrasound in Obstetrics and Gynecology, 2020, 56, 422-430.	0.9	19
100	Current Status of Noninvasive Prenatal Testing and Counselling Considerations: An Indian Perspective. Journal of Fetal Medicine, 2020, 07, 9-16.	0.1	3
101	Prospective clinical evaluation of Momguard non-invasive prenatal test in 1011 Korean high-risk pregnant women. Journal of Obstetrics and Gynaecology, 2020, 40, 1090-1095.	0.4	2
102	Fetal fraction and noninvasive prenatal testing: What clinicians need to know. Prenatal Diagnosis, 2020, 40, 155-163.	1.1	82
103	Human Papillomavirus Infections in Pregnant Women and Its Impact on Pregnancy Outcomes: Possible Mechanism of Self-Clearance. , 0, , .		3
104	Prenatal screening in the era of non-invasive prenatal testing: a Nationwide cross-sectional survey of obstetrician knowledge, attitudes and clinical practice. BMC Pregnancy and Childbirth, 2020, 20, 579.	0.9	9
105	Should Vanishing Twin Pregnancies Be Systematically Excluded From Cellâ€Free Foetal Dna Testing?. Prenatal Diagnosis, 2020, 41, 1241-1248.	1.1	20
106	The Level of Free Fetal DNA as Precise Noninvasive Marker for Chromosomal Aneuploidies: First Results from BALTIC Region. Medicina (Lithuania), 2020, 56, 579.	0.8	4
107	Recent Advances in the Noninvasive Prenatal Testing for Chromosomal Abnormalities Using Maternal Plasma DNA. Journal of Fetal Medicine, 2020, 7, 17-23.	0.1	1
108	Noninvasive prenatal testing and maternal obesity: A review. Acta Obstetrica Et Gynecologica Scandinavica, 2020, 99, 744-750.	1.3	12
109	Most noninvasive prenatal screens failing due to inadequate fetal cell free <scp>DNA</scp> are negative for trisomy when repeated. Prenatal Diagnosis, 2020, 40, 831-837.	1.1	12
112	Nonâ€invasive prenatal testing in the management of twin pregnancies. Prenatal Diagnosis, 2021, 41, 1233-1240.	1.1	23
113	Association between low fetal fraction in cellâ€free DNA testing and adverse pregnancy outcome: A systematic review. Prenatal Diagnosis, 2021, 41, 1287-1295.	1.1	16
114	Dropletâ€based digital PCR for nonâ€invasive prenatal genetic diagnosis of Î± and Î²â€thalassemia. Biomedical Reports, 2021, 15, 82.	0.9	15
115	Low fetal fraction in cellâ€free DNA testing is associated with adverse pregnancy outcome: Analysis of a subcohort of the TRIDENTâ€2 study. Prenatal Diagnosis, 2021, 41, 1296-1304.	1.1	13

#	ARTICLE	IF	CITATIONS
116	Non-invasive prenatal testing 10 years on. <i>Prenatal Diagnosis</i> , 2021, 41, 1187-1189.	1.1	3
117	More attention should be paid to pregnant women who fail non-invasive prenatal screening. <i>Clinical Biochemistry</i> , 2021, 96, 33-37.	0.8	4
119	Recent trends in prenatal genetic screening and testing. <i>F1000Research</i> , 2019, 8, 764.	0.8	46
120	False Negative NIPT Results: Risk Figures for Chromosomes 13, 18 and 21 Based on Chorionic Villi Results in 5967 Cases and Literature Review. <i>PLoS ONE</i> , 2016, 11, e0146794.	1.1	45
121	Non-Invasive Prenatal Testing: Current Perspectives and Future Challenges. <i>Genes</i> , 2021, 12, 15.	1.0	36
122	Integrity of cell-free DNA in maternal plasma extracellular vesicles as a potential biomarker for non-invasive prenatal testing. <i>International Journal of Gynecology and Obstetrics</i> , 2022, 158, 406-417.	1.0	4
123	Fehlbildungsdiagnostik und Ultraschalluntersuchung im 1. Trimenon. , 2015, , 1-22.		0
124	Fehlbildungsdiagnostik und Ultraschalluntersuchung im 1. Trimenon. , 2016, , 129-143.		0
126	Estado actual de las aplicaciones del ADN libre de c�lula circulante. <i>Medicina Y Laboratorio</i> , 2017, 23, 551-564.	0.0	0
127	A multivariate modeling method for the prediction of low fetal fraction before noninvasive prenatal testing. <i>Science Progress</i> , 2021, 104, 003685042110523.	1.0	0
128	Low Fetal Fraction of Cell-free DNA Identified by Non-invasive Prenatal DNA Testing: Possible Causes, Clinical Significance, and Tactics. <i>Doctor Ru</i> , 2020, 19, 49-54.	0.1	1
129	Effect of preexamination conditions in a centralized-testing model of non-invasive prenatal screening. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, .	1.4	0
130	Simulated confined placental mosaicism proportion (SCPMP) based on cell-free fetal DNA fraction enrichment can reduce false-positive results in non-invasive prenatal testing. <i>Prenatal Diagnosis</i> , 2022, 42, 1008-1014.	1.1	1
132	Low Fetal Fraction of Cell Free DNA at Non-Invasive Prenatal Screening Increases the Subsequent Risk of Preterm Birth in Uncomplicated Singleton Pregnancy. <i>International Journal of Women's Health</i> , 0, Volume 14, 889-897.	1.1	2
133	Chromosomal phase improves aneuploidy detection in non-invasive prenatal testing at low fetal DNA fractions. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
135	Non-invasive prenatal screening tests�� update 2022. <i>Laboratoriums Medizin</i> , 2022, 46, 311-320.	0.1	3
136	Progressive trends in prenatal genetic screening. <i>Iberoamerican Journal of Medicine</i> , 2022, 4, 229-236.	0.1	0
137	Current Perspectives of Prenatal Cell-free DNA Screening in Clinical Management of First-Trimester Septated Cystic Hygroma. <i>International Journal of Women's Health</i> , 0, Volume 14, 1499-1518.	1.1	2



#	ARTICLE	IF	CITATIONS
138	Positive predictive value of single nucleotide polymorphism (SNP)-based NIPT for aneuploidy in twins: EXPERIENCE FROM CLINICAL PRACTICE. Prenatal Diagnosis, 0, , .	1.1	5
139	Inconsistency between non-invasive prenatal testing (NIPT) and conventional prenatal diagnosis due to confined placental and fetal mosaicism: Two case reports. Frontiers in Medicine, 0, 9, .	1.2	4
140	Correlation of low fetal fraction of cell-free DNA at the early second-trimester and pregnancy complications related to placental dysfunction in twin pregnancy. Frontiers in Medicine, 0, 9, .	1.2	0
141	Performance of a cfDNA prenatal screening test, choice of prenatal procedure, and chromosome conditions identified during pregnancy after low-risk cfDNA screening. Prenatal Diagnosis, 0, , .	1.1	1
142	Maternal and fetal factors influencing fetal fraction: A retrospective analysis of 153,306 pregnant women undergoing noninvasive prenatal screening. Frontiers in Pediatrics, 0, 11, .	0.9	0
143	Noninvasive prenatal testing/screening by circulating cell-free DNA. , 2023, , 823-851.		0
144	Nucleic Acid in Diagnostics. , 2023, , 213-269.		0